Trials Confirm Lorundrostat Effectively Lowers Blood Pressure
Aldosterone synthase inhibitor may offer a new option for patients with resistant or uncontrolled hypertension
Topline
Lorundrostat, a novel aldosterone synthase inhibitor, significantly reduced systolic blood pressure in patients with uncontrolled or resistant hypertension across two pivotal trials, supporting its potential as a next-generation add-on therapy.
Study Details
Mineralys Therapeutics recently announced positive topline results from two major clinical …
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.